Abstract Background Coronavirus disease 2019 (COVID-19) has killed over 2.5 million
people worldwide, but effective care and therapy have yet to be discovered. We conducted …

Background Tocilizumab, a drug targeting interleukin-6 administrated in the right timeframe
may be beneficial in coronavirus-disease-2019 (COVID-19). We aimed to assess its benefit …

Background Coronavirus disease-2019 (COVID-19), a worldwide disaster, has already
affected lots of people. Effective care and therapy are currently being evaluated in full swing …

Introduction The results of studies of tocilizumab (TCZ) in COVID‐19 are contradictory. Our
study aims to update medical evidence from controlled observational studies and …

Background No therapy is approved for COVID-19 pneumonia. The aim of this study was to
assess the role of tocilizumab in reducing the risk of invasive mechanical ventilation and …

Objective Elevated levels of pro-inflammatory cytokines are observed in severe COVID-19
infections, and cytokine storm is associated with disease severity. Tocilizumab, an …

Background COVID-19 is an ongoing threat to society. Patients who develop the most
severe forms of the disease have high mortality. The interleukin-6 inhibitor tocilizumab has …

Background: Since December 2019, the coronavirus disease (COVID-19) has spread
worldwide, leading to a global health threat. This study aimed to investigate the …

Background This meta-analysis was conducted to investigate the impact of tocilizumab on
clinical outcomes associated with COVID-19. Methods A comprehensive search was …

Background Interleukin-6 (IL-6)-mediated hyperinflammation may contribute to the high
mortality of coronavirus disease 2019 (Covid-19). Tocilizumab, an IL-6 receptor blocking …